(FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) were used to detect liver fibrosis in the patients. The agreement between FS and the other methods was evaluated. To 
INTRODUCTION
Highly active antiretroviral therapy (HAART) has dramatically changed the course of HIV infection, with a decrease in morbidity and mortality derived from classical opportunistic infections [1] [2] [3] . Abnormal liver function tests are common and may be caused by HIV itself, hepatitis viruses, systemic opportunistic infections, malignancies, and drug-induced hepatotoxicity [4] [5] [6] [7] . There are four major classes of HAART: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and integrase inhibitors. Hepatotoxicity, liver enzyme elevation, and drug interactions are significant problems in patients with HIV who are on HAART [8, 9] . In patients commencing antiretroviral therapy, 14-20% will experience elevations of liver enzymes and 2-10% will require interruption of antiretroviral therapy due to severe hepatic injury and a marked elevation of liver enzymes [10, 11] . There are multiple pathogenetic mechanisms involved in hepatotoxicity, including direct drug toxicity, immune reconstitution in the presence of hepatitis C virus (HCV) and/or hepatitis B virus (HBV) coinfections, hypersensitivity reactions with liver involvement, and mitochondrial toxicity [12] .
Other pathogenetic pathways may be involved, such as insulin resistance caused by several antiretrovirals, which may contribute to the development of steatohepatitis. The relationship between drug toxicity and the development of liver fibrosis or liver cirrhosis is still unclear.
Different non-invasive methods have been described to detect liver fibrosis or liver cirrhosis. Most of these scores use serum markers [13] . In the past few years, transient elastography [FibroScan Ò (FS); Echosens] has gained an important role in the detection of liver fibrosis. FS is a simple, non-invasive method of assessing liver fibrosis by measuring liver stiffness [14] . A good correlation has been found between the stage of liver fibrosis and the measured liver stiffness [15] [16] [17] .
In this study, the authors compared different non-invasive methods of detecting liver fibrosis/cirrhosis in patients who were HIV positive. Furthermore, to identify the drug classes that are associated with liver damage the duration of medication intake was correlated with the results of FS.
METHODS

Patients
Patients who were HIV positive and who had given their informed consent were included into this cross-sectional study performed at the 
Liver Stiffness Measured by FS
Details of the technical background and examination procedure have been described previously [14] . Patients had been fasting for at least 8 h when FS was performed. Blood tests were taken just before performance of FS. The tip of the probe transducer was placed on the skin between the rib bones and the level of the right lobe of the liver. The measurement depth was between 25 and 65 mm below the skin surface. Ten measurements were performed with success rates of at least 60% and the interquartile range did not exceed 30% of the median value. The results were expressed in kiloPascal (kPa). The median value was taken as representative. A good correlation has been established with Metavir scores as follows: F0-F1, \7.1 kPa; F2-F3, 7.1-12.5 kPa; and F4, [12.5 kPa [16] .
Aspartate Aminotransferase to Platelet Ratio Index
The aspartate aminotransferase (AST) to platelet ratio index (APRI) was calculated using the formula APRI = AST level/(upper limit of normal [ULN]) 9 100/platelet count (10 9 /L) and categorized according to cutoffs defined by Wai et al. [18] : \0.5, no significant fibrosis; 0.5-1.5 fibrosis; \1.5, cirrhosis).
Hyaluronic Acid
Hyaluronic acid (HA) levels (ng/ml) were assessed in serum samples, stored at -80°C, using a commercially available enzyme-linked immunosorbent assay (Corgenix, Broomfield, CO, USA). The following previously published [19] HA cutoff values were used: \75 ng/ml, no significant fibrosis; 75-110 ng/ml, fibrosis; [ 110 ng/ml, cirrhosis.
Hepascore
The Hepascore (HS) was calculated from the following equation 
Carbohydrate-Deficient Transferrin
Carbohydrate-Deficient Transferrin (CDT) was taken as a marker for increased alcohol intake.
CDT performed best as an alcohol biomarker in comparison with other biomarkers, with a sensitivity of 67% and specificity of 71% for detecting an average consumption of more than 40 g per day versus less [21] .
Fibrosis-4
The Fibrosis-4 (FIB-4) values were calculated automatically using the formula: age Laboratories, North Chicago, IL, USA).
Statistical Analysis
Data were entered in SPSS (version 11.0, SPSS Inc., A logistic regression was performed to identify independent factor that was associated with the increase of liver stiffness. The significance level was set at 0.05 and all P values were two tailed.
Munich, Germany
RESULTS
A total of 203 (148 men and 55 women, mean age 47 ± 11 years) consecutive patients who were HIV positive were enrolled in the study.
Patients' characteristics are shown in Table 1 .
Fifty-one patients were at HIV stage CDC A, 69 patients were at stage CDC B, and 83 patients were at stage CDC C. To investigate the influence of HAART on the liver stiffness, the liver stiffness was correlated with the duration (months) of medication for each substance group (NRTI, NNRT, and PI). Based on the fact that only four patients received integrase inhibitors, this substance group was not correlated with FS. All patients with any positive marker for HBV (HBs-Ag positive, n = 11) or HCV (hepatitis C virus antibody positive, n = 16; HCV-RNA positive, n = 8) infection were excluded. CDT was taken as a marker for increased alcohol intake. Patients with a CDT above the ULN (2.5%) were also excluded. A total of 153 patients remained for the analysis. Liver (11.7%) patients, and was above 12.5 kPa in one patient (0.6%). Statistical analyses were only done between patients with a liver stiffness below 7.1 kPa and patients with a liver stiffness between 7.1 and 12.5 kPa (Table 3) .
Therapy duration with each substance group was correlated with the measured liver stiffness.
Therapy duration with PI ranged from 0 to 124 months (mean 28 ± 31 months). Liver stiffness showed a positive, statistically significant correlation with the duration of PI intake (r = 0.18; P = 0.026; Table 4 ). Therapy duration of NRTI (mean 55 ± 44 months; range 0-188 months; r = 0.044; P = 0.59) and NNRTI (mean 24 ± 28 months; range 0-105 months; r = -0.6; P = 0.461) did not correlate with liver stiffness. No significant correlation could be observed between liver stiffness and age (P = 0.25), sex (P = 0.12), race (P = 0.13 for white patients vs. black patients), or BMI (P = 0.22), so these factors could be excluded as being confounding. To identify therapy duration with PI as an independent factor for the increase of liver stiffness, a logistic regression was performed including the factors BMI, age, sex, race, and therapy duration with PI. Therapy duration was the only factor that was significantly associated with liver stiffness [P = 0.049; 95% confidence interval (CI) 0.056-0.964].
DISCUSSION
HAART has dramatically changed the course of HIV infection, and has decreased the morbidity and mortality derived from classical opportunistic infections [23] . Therapy is effective in most cases and well tolerated in a substantial proportion of patients, but adverse events, such as hypersensitivity reactions and hepatotoxicity, are relatively common [24, 25] . Therapy with PIs is more often associated with liver enzyme elevation than with NRTIs or NNRTIs. Long-term effects of HAART in developing liver fibrosis/cirrhosis have not been sufficiently studied. This may in part be explained by the fact that liver biopsy is the gold standard for the detection of liver fibrosis/cirrhosis, but is an invasive method with associated complications [26] .
Furthermore, to study the development of liver fibrosis under HAART, repeated liver biopsies are difficult to justify due to the associated risk and discomfort. Different noninvasive methods are available to detect liver fibrosis/cirrhosis. Being aware that these tests [27] [28] [29] . Taking this into account, only patients who were fasting and had no sign of acute hepatitis or cholestasis were included in the current study.
A total of 203 patients were included in this cross-sectional analysis. In the first step, the extent of agreement between the different tests was compared. Based on the fact that FS has been evaluated in liver diseases of different origin, FS was chosen as the reference. The comparison between the methods showed a comparable stage of fibrosis in 64% to 77% of patients. This comparison between these methods is limited by the fact that HS, HA, FIB-4, and APRI are not designed to assess fatty liver disease. An excellent correlation has been shown for non-alcoholic fatty liver disease and FS [30] .
To study the role of the different substance groups (PI, NRTI, and NNRTI) in developing liver fibrosis/cirrhosis, FS was correlated with the duration of medication intake for each group. Because of the limited number of patients who received integrase inhibitors, the effect of this substrate group could not be studied. Additional factors, which may lead to liver fibrosis/cirrhosis, were largely eliminated by excluding patients with chronic HBV or HCV infection and patients with evidence of chronic alcohol abuse. A total of 153 patients remained for this analysis. We found a significant correlation of the liver stiffness with the duration of PI intake, but not with the duration of NTRI or NNRTI intake. . Dose-dependent hepatotoxicity may result from toxic levels of drugs whose clearance is reduced. The results of the current study underline the hepatotoxicity of PIs and the association of long-term drug use with the development of liver fibrosis. This correlation has to be investigated in a longer prospective study. The acceptance of repeated measurements with the non-invasive methods can be improved, so that prospective studies to detect drug induced hepatotoxicity can be performed. The weakness of the current study is that it is a cross-sectional study. All patients underwent FS once, so that possible progression of the liver stiffness could not be detected. 
CONCLUSION
The agreement between FS and the other tests was 64% to 77%. A significant correlation was found for liver stiffness and the duration of therapy with PI, which underlines the known hepatotoxicity of this substance group. Patients receiving PI should be monitored to detect hepatotoxicity and avoid long-term complications such as liver cirrhosis. FS is a simple method of assessing liver fibrosis and can be used in regular clinical routine.
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